Ashley A. Dunham
Duke University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ashley A. Dunham.
Journal of clinical & translational endocrinology | 2015
Susan E. Spratt; Bryan C. Batch; Lisa P. Davis; Ashley A. Dunham; Michele Easterling; Mark N. Feinglos; Bradi B. Granger; Gayle Harris; Michelle Lyn; Pamela Maxson; Bimal R. Shah; Benjamin Strauss; Tainayah Thomas; Robert M. Califf; Marie Lynn Miranda
Objective The Durham Diabetes Coalition (DDC) was established in response to escalating rates of disability and death related to type 2 diabetes mellitus, particularly among racial/ethnic minorities and persons of low socioeconomic status in Durham County, North Carolina. We describe a community-based demonstration project, informed by a geographic health information system (GHIS), that aims to improve health and healthcare delivery for Durham County residents with diabetes. Materials and Methods A prospective, population-based study is assessing a community intervention that leverages a GHIS to inform community-based diabetes care programs. The GHIS integrates clinical, social, and environmental data to identify, stratify by risk, and assist selection of interventions at the individual, neighborhood, and population levels. Results The DDC is using a multifaceted approach facilitated by GHIS to identify the specific risk profiles of patients and neighborhoods across Durham County. A total of 22,982 patients with diabetes in Durham County were identified using a computable phenotype. These patients tended to be older, female, African American, and not covered by private health insurance, compared with the 166,041 persons without diabetes. Predictive models inform decision-making to facilitate care and track outcomes. Interventions include: 1) neighborhood interventions to improve the context of care; 2) intensive team-based care for persons in the top decile of risk for death or hospitalization within the coming year; 3) low-intensity telephone coaching to improve adherence to evidence-based treatments; 4) county-wide communication strategies; and 5) systematic quality improvement in clinical care. Conclusions To improve health outcomes and reduce costs associated with type 2 diabetes, the DDC is matching resources with the specific needs of individuals and communities based on their risk characteristics.
Drug and Alcohol Dependence | 2015
Li-Tzy Wu; Udi E. Ghitza; Bryan C. Batch; Michael J. Pencina; Leoncio Flavio Rojas; Benjamin A. Goldstein; Tony Schibler; Ashley A. Dunham; Shelley A. Rusincovitch; Kathleen T. Brady
BACKGROUND Comorbid diabetes and substance use diagnoses (SUD) represent a hazardous combination, both in terms of healthcare cost and morbidity. To date, there is limited information about the association of SUD and related mental disorders with type 2 diabetes mellitus (T2DM). METHODS We examined the associations between T2DM and multiple psychiatric diagnosis categories, with a focus on SUD and related psychiatric comorbidities among adults with T2DM. We analyzed electronic health record (EHR) data on 170,853 unique adults aged ≥18 years from the EHR warehouse of a large academic healthcare system. Logistic regression analyses were conducted to estimate the strength of an association for comorbidities. RESULTS Overall, 9% of adults (n=16,243) had T2DM. Blacks, Hispanics, Asians, and Native Americans had greater odds of having T2DM than whites. All 10 psychiatric diagnosis categories were more prevalent among adults with T2DM than among those without T2DM. Prevalent diagnoses among adults with T2MD were mood (21.22%), SUD (17.02%: tobacco 13.25%, alcohol 4.00%, drugs 4.22%), and anxiety diagnoses (13.98%). Among adults with T2DM, SUD was positively associated with mood, anxiety, personality, somatic, and schizophrenia diagnoses. CONCLUSIONS We examined a large diverse sample of individuals and found clinical evidence of SUD and psychiatric comorbidities among adults with T2DM. These results highlight the need to identify feasible collaborative care models for adults with T2DM and SUD related psychiatric comorbidities, particularly in primary care settings, that will improve behavioral health and reduce health risk.
Frontiers in Pharmacology | 2013
Bradi B. Granger; Shelley A. Rusincovitch; Suzanne Avery; Bryan C. Batch; Ashley A. Dunham; Mark N. Feinglos; Katherine Kelly; Marjorie Pierre-Louis; Susan E. Spratt; Robert M. Califf
Purpose: Poor adherence to prescribed medicines is associated with increased rates of poor outcomes, including hospitalization, serious adverse events, and death, and is also associated with increased healthcare costs. However, current approaches to evaluation of medication adherence using real-world electronic health records (EHRs) or claims data may miss critical opportunities for data capture and fall short in modeling and representing the full complexity of the healthcare environment. We sought to explore a framework for understanding and improving data capture for medication adherence in a population-based intervention in four U.S. counties. Approach: We posited that application of a data model and a process matrix when designing data collection for medication adherence would improve identification of variables and data accessibility, and could support future research on medication-taking behaviors. We then constructed a use case in which data related to medication adherence would be leveraged to support improved healthcare quality, clinical outcomes, and efficiency of healthcare delivery in a population-based intervention for persons with diabetes. Because EHRs in use at participating sites were deemed incapable of supplying the needed data, we applied a taxonomic approach to identify and define variables of interest. We then applied a process matrix methodology, in which we identified key research goals and chose optimal data domains and their respective data elements, to instantiate the resulting data model. Conclusions: Combining a taxonomic approach with a process matrix methodology may afford significant benefits when designing data collection for clinical and population-based research in the arena of medication adherence. Such an approach can effectively depict complex real-world concepts and domains by “mapping” the relationships between disparate contributors to medication adherence and describing their relative contributions to the shared goals of improved healthcare quality, outcomes, and cost.
Primary Care Diabetes | 2017
Courtney Harold Van Houtven; Melissa A. Greiner; Brooke L Heidenfelder; Susan E. Spratt; Bradi B. Granger; Ashley A. Dunham; Laura G. Qualls; Lesley H. Curtis
AIMS Type 2 diabetes mellitus imposes significant burdens on patients and health care systems. Population-level interventions are being implemented to reach large numbers of patients at risk of or diagnosed with diabetes. We describe a population-based evaluation of the Southeastern Diabetes Initiative (SEDI) from the perspective of a payer, the Centers for Medicare & Medicaid Services (CMS). The purpose of this paper is to describe the population-based evaluation approach of the SEDI intervention from a Medicare utilization and cost perspective. METHODS We measured associations between the SEDI intervention and receipt of diabetes screening (i.e., HbA1c test, eye exam, lipid profile), health care resource use, and costs among intervention enrollees, compared with a control cohort of Medicare beneficiaries in geographically adjacent counties. RESULTS The intervention cohort had slightly lower 1-year screening in 2 of 3 domains (4% for HbA1c; 9% for lipid profiles) in the post-intervention period, compared with the control cohort. The SEDI intervention cohort did not have different Medicare utilization or total Medicare costs in the post-intervention period from surrounding control counties. CONCLUSIONS Our analytic approach may be useful to others evaluating CMS demonstration projects in which population-level health is targeted for improvement in a well-defined clinical population.
American Journal of Translational Research | 2012
Jessica D. Tenenbaum; Christian; Cornish Ma; Rowena J Dolor; Ashley A. Dunham; Geoffrey S. Ginsburg; Virginia B. Kraus; John G. McHutchison; Meredith Nahm; L. K Newby; Laura P. Svetkey; Krishna Udayakumar; Robert M. Califf
American Journal of Translational Research | 2012
Bhattacharya S; Ashley A. Dunham; Cornish Ma; Christian Va; Geoffrey S. Ginsburg; Jessica D. Tenenbaum; Meredith Nahm; Marie Lynn Miranda; Robert M. Califf; Rowena J Dolor; L. K Newby
american medical informatics association annual symposium | 2010
Constance M. Johnson; Meredith Nahm; Ryan J. Shaw; Ashley A. Dunham; Kristin Newby; Rowena J Dolor; Michelle Smerek; Guilherme Del Fiol; Jiajie Zhang
American Journal of Translational Research | 2014
Strauss Bw; Valentiner Em; Bhattacharya S; Smerek Mm; Ashley A. Dunham; L. K Newby; Marie Lynn Miranda
Contemporary Clinical Trials | 2016
Li-Tzy Wu; Kathleen T. Brady; Susan E. Spratt; Ashley A. Dunham; Brooke L Heidenfelder; Bryan C. Batch; Robert Lindblad; Paul VanVeldhuisen; Shelley A. Rusincovitch; Therese K. Killeen; Udi E. Ghitza
AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science | 2013
Shelley A. Rusincovitch; Bryan C. Batch; Susan E. Spratt; Bradi B. Granger; Ashley A. Dunham; Lisa P. Davis; Stephanie Brinson; Jeffrey M. Ferranti; Howard Shang; Robert M. Califf